<DOC>
	<DOC>NCT02951026</DOC>
	<brief_summary>This long-term extension study is designed to monitor the long-term safety, tolerability, and efficacy of treatment of SM04690 or placebo previously injected in the target knee joints of subjects with moderately to severely symptomatic osteoarthritis (OA) from a Samumed-sponsored SM04690-OA phase 2 or phase 3 study. No additional SM04690 or placebo therapy will be administered in this study.</brief_summary>
	<brief_title>An Observational Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Completion of scheduled endofstudy visit of Samumedsponsored SM04690OA phase 2 or phase 3 studies Full understanding of the requirements of the study and willingness to comply with all study visits and assessments Subjects must have read and understood the informed consent form, and must have signed it prior to any studyrelated procedure being performed Unable to undergo the radiograph procedures detailed within the protocol Partial or complete joint replacement in the target knee Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the investigative site, or are directly affiliated with the study at the investigative site Subjects employed by Samumed, LLC, or any of its affiliates or development partners (that is, an employee, temporary contract worker, or designee) responsible for the conduct of the study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>knee</keyword>
	<keyword>osteoarthritis</keyword>
	<keyword>intra-articular injection</keyword>
	<keyword>SM04690</keyword>
</DOC>